



DIASORIN IS COLLABORATING WITH LUMOS DIAGNOSTICS TO LAUNCH THE LIAISON® IQ, A NEW IMMUNOASSAY POINT-OF-CARE PLATFORM, AND THE FIRST TWO ASSAYS FOR DECENTRALIZED COVID-19 TESTING

- DIASORIN ANNOUNCES ITS STRATEGIC COLLABORATION WITH LUMOS DIAGNOSTICS, A POINT-OF-CARE (POC) DIAGNOSTIC SPECIALIST TO LAUNCH ITS FIRST IMMUNOASSAY POINT-OF-CARE PLATFORM
- LIAISON® IQ WILL BE THE NEW DIASORIN LATEST GENERATION CLIA-WAIVED IMMUNOASSAY POC PLATFORM TO ADDRESS LATERAL-FLOW TESTING MARKET
- LIAISON® IQ WILL BE AVAILABLE IN MARKETS ACCEPTING THE CE MARK WITHIN Q2 2021 AND IN THE U.S. MARKET AFTER RECEIVING AUTHORIZATION FROM THE U.S. FDA
- LIAISON® IQ IS A PORTABLE, CLOUD-CONNECTION ENABLED DEVICE, WHICH PROVIDES CORE LABORATORY QUALITY RESULTS AND TRACEABILITY IN DECENTRALIZED NEAR-PATIENT SETTINGS
- THE FIRST ASSAYS TO BE LAUNCHED ON THE LIAISON® IQ WITHIN Q2 2021 ARE A TEST TO DETECT IGG ANTIBODIES AGAINST SARS-CoV-2 IN HUMAN CAPILLARY BLOOD FROM A FINGERSTICK AND AN ANTIGEN TEST FOR COVID-19 DETECTION THROUGH NASAL SWAB.

Saluggia, April 6, 2021 - DiaSorin (FTSE MIB: DIA) announces its strategic collaboration with Lumos Diagnostics, diagnostic specialists with experience in the customized development and manufacturing of rapid, high-quality and cutting-edge point-of-care (POC) diagnostic test solutions. The collaboration will allow DiaSorin to launch the LIAISON® IQ, the new portable and cloud-connection enabled immunoassay POC reader together with a test to detect specific IgG antibodies against SARS-CoV-2 Spike Protein in human capillary blood from a fingerstick, followed by an antigen test for COVID-19 detection in nasal swabs.

The LIAISON® IQ and the first two tests will be available in markets accepting CE Mark within Q2 2021 and will be submitted to the U.S. Food and Drug Administration for Emergency Use Authorization.

The launch of the new DiaSorin Immunoassay POC platform follows the strategy to address the decentralization trend in diagnostics, with CLIA-waived and cost-effective POC solutions that provide answers in less than 15 minutes. The LIAISON® IQ, together with the molecular diagnostic system currently under development, will allow DiaSorin to develop a complete set of assays to address the decentralized space with a unique product offering.

DiaSorin is planning to expand rapidly the menu of LIAISON® IQ beyond COVID-19 related tests in diversified clinical areas (e.g. other infectious diseases such as Lyme disease or gastrointestinal tract infections), where DiaSorin is offering a full spectrum of products and is a reference brand leader in the central laboratory segment.

POC testing is gaining traction in the diagnostic market, driven by an increased need for efficiency and the decentralization of a relevant portion of existing current testing volume, the latter due to the growing prevalence of infectious diseases and the need to reduce the time from diagnosis to a more precise treatment.

The LIAISON® IQ ensures superior quality testing in POC settings and it has been designed to make testing more accessible, guarantee traceability of patients' results and provide a better experience for



users. The platform is based on latest generation technology, with a user-friendly interface, a tablet to easily control the workflow and the connection to the cloud through Wi-Fi and mobile networks.

The LIAISON® IQ leverages on the Group expertise in developing reliable and innovative immunodiagnostic tests, pairing with its strategy for the development of a molecular diagnostic POC platform, initiated in March of 2020.

“Our first immunodiagnostic solution in decentralized locations will be key to respond to the current emergency created by the COVID-19 pandemic,” commented Carlo Rosa, CEO of DiaSorin Group. “The collaboration with Lumos opens for us a new business opportunity that we want to pursue, as we believe that the success of decentralized testing will depend on the ability of a supplier to guarantee on the POC platforms the same level of quality and traceability currently available in the central laboratories. In the near future, the same patient may be tested in a hospital lab or a decentralized diagnostic setting and the result of the test has to be comparable. The POC market is one of the channels of our business growth, on top of our existing diagnostic offer for laboratories, bringing our knowledge in developing new cutting-edge tests to a new, simple and cost-effective platform.”





For additional information, please contact:

For DiaSorin

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39.0161.487567

emanuela.salvini@diasorin.it

For Lumos Diagnostics

Laura Lovejoy Sambursky

Saranova, LLC – Strategic Corporate Marketing and Communications

Tel: +1.941.928.9025

communications@lumosdiagnostics.com

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.

For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases with unmet diagnostic needs. For more information visit lumosdiagnostics.com.